Recombinant Kluyveromyces lactis expressing highly pathogenic porcine reproductive and respiratory syndrome virus GP5 elicits mucosal and cell-mediated immune responses in mice.
10.4142/jvs.2014.15.2.199
- Author:
Haiyan ZHAO
1
;
Yalan WANG
;
Zhitao MA
;
Yongqiang WANG
;
Wen Hai FENG
Author Information
1. State Key Laboratory of Agrobiotechnology, Key Laboratory of Soil Microbiology, Department of Microbiology and Immunology, College of Biological Sciences, China Agricultural University, Beijing 100193, China. whfeng@cau.edu.cn
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
GP5;
immune responses;
Kluyveromyces lactis yeast;
PRRSV;
vaccine
- MeSH:
Administration, Oral;
Animals;
Antibodies, Viral/*immunology;
B-Lymphocytes/immunology/virology;
Enzyme-Linked Immunosorbent Assay;
*Immunity, Cellular;
*Immunity, Mucosal;
Injections, Subcutaneous;
Kluyveromyces/genetics;
Mice;
Mice, Inbred BALB C;
Porcine respiratory and reproductive syndrome virus/*immunology;
Recombinant Proteins/genetics/immunology;
T-Lymphocytes/immunology/virology;
Viral Envelope Proteins/*genetics/*immunology;
Viral Vaccines/administration & dosage/*pharmacology
- From:Journal of Veterinary Science
2014;15(2):199-208
- CountryRepublic of Korea
- Language:English
-
Abstract:
Currently, killed-virus and modified-live porcine reproductive and respiratory syndrome virus (PRRSV) vaccines are used to control porcine reproductive and respiratory syndrome. However, both types of vaccines have inherent drawbacks; accordingly, the development of novel PRRSV vaccines is urgently needed. Previous studies have suggested that yeast possesses adjuvant activities, and it has been used as an expression vehicle to elicit immune responses to foreign antigens. In this report, recombinant Kluyveromyces lactis expressing GP5 of HP-PRRSV (Yeast-GP5) was generated and immune responses to this construct were analyzed in mice. Intestinal mucosal PRRSV-specific sIgA antibody and higher levels of IFN-gamma in spleen CD4+ and CD8+ T cells were induced by oral administration of Yeast-GP5. Additionally, Yeast-GP5 administered subcutaneously evoked vigorous cell-mediated immunity, and PRRSV-specific lymphocyte proliferation and IFN-gamma secretion were detected in the splenocytes of mice. These results suggest that Yeast-GP5 has the potential for use as a vaccine for PRRSV in the future.
